GT BIOPHARMA

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors... GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology.

Also known as: GT Biopharma, Inc.

Primary location: Brisbane United States